01/28/2025

Novo Nordisk to Cap Insulin Prices in Minnesota Settlement

It will join Lilly, Sanofi by doing so

Novo Nordisk agreed to cap insulin prices to settle a lawsuit in which Minnesota's attorney general accused the three largest insulin makers of charging astronomically high prices for the diabetes drug.

The settlement filed on Monday in the Newark, New Jersey federal court follows similar settlements last year with Eli Lilly and French drugmaker Sanofi.

It requires Novo Nordisk to cap out-of-pocket costs for patients who pay with cash at $35 per monthly prescription, regardless of whether the patients have insurance.

Please select this link to read the complete article from Reuters.